01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
is retatrutide a glp 1 drug Retatrutide, GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide: 24% Weight Loss Without
Description
Maier JA, et al
Seventy-four participants in each cohort were excluded for having a pre-existing diagnosis of heart failure
Among those people, about 10% are severely obese, meaning they have BMIs of 40 or greater
A positive outcome of adding Wegovy to formularies is the reduction of inappropriate use of Ozempic for indications other than diabetes
Get irrefutable data about your diet and lifestyle by using your own glucose data with Vivelys CGM Program
That drug had no effect
